Trial Profile
A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ATALANTE
- 27 Mar 2024 This trial has been completed in France (Global end date: 22 Feb 2024).
- 29 Aug 2023 Results published in the Journal of Clinical Oncology
- 13 Sep 2022 Primary endpoint has not been met (Efficacy: Progression free survival, where the date of progression is based on investigator assessment using the RECIST version 1.1) , according to Results presented at the 47th European Society for Medical Oncology Congress